Company: AGIO
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0001439222-25-000036
Chunk: 75

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 1
Chunk 75
---
 and noncredit-related impairment is recognized in other comprehensive income, net of taxes. Realized gains and losses are included in investment income on a specific-identification basis. There were no material realized gains or losses on marketable securities for the three months ended March 31, 2025 or 2024.Marketable securities at March 31, 2025 consisted of the following:(In thousands)AmortizedCostUnrealizedGainsUnrealizedLossesFairValueCurrent:Certificates of deposit$6,758 $5 $— $6,763 U.S. Treasuries127,826 95 (102)127,819 Government securities157,990 27 (88)157,929 Corporate debt securities521,864 278 (242)521,900 Total Current814,438 405 (432)814,411 Non-current:U.S. Treasuries105,858 476 (42)106,292 Government securities114,181 27 (173)114,035 Corporate debt securities310,822 390 (286)310,926 Total Non-current530,861 893 (501)531,253 Total marketable securities$1,345,299 $1,298 $(933)$1,345,664 Marketable securities at December 31, 2024 consisted of the following:(In thousands)AmortizedCostUnrealizedGainsUnrealizedLossesFairValueCurrent:Certificates of deposit$10,374 $11 $— $10,385 U.S. Treasuries173,465 153 (27)173,591 Government securities167,970 103 (75)167,998 Corporate debt securities465,427 321 (259)465,489 Total Current817,236 588 (361)817,463 Non-current:U.S. Treasuries107,725 106 (303)107,528 Government securities112,175 3 (469)111,709 Corporate debt securities420,166 181 (1,263)419,084 Total Non-current640,066 290 (2,035)638,321 Total marketable securities$1,457,302 $878 $(2,396)$1,455,784 As of March 31, 2025 and December 31, 2024